Many cancers have unknown genetic background, so sequencing the whole genome gives researchers the opportunity to link cancer phenotypes to genotypes. For specific cancer types, the use of targeted genomic panels for both germline susceptibility and known “actionable” somatic mutations is becoming routine in many cancer centers (De Leeneer et al. Our state-of-the-art clinical, sequencing, bioinformatics and proteomics platforms are ready to be put to use for your research or clinic. Although cancer research is relying more on whole-genome c … The human genome is made up of over three billion DNA base pairs. Creative Biolabs has established the high-throughput SuPrecision™ platform for large-scale sequencing services. With DNA sequencing costs falling, the TCGA and the International Cancer Genome Consortium turned to the entire genome about 10 years ago, sequencing all … The center includes the Ion Proton and Ion PGM Sequencing Platforms as NGS technology, there are multiple sequencing options such as Whole Genome, RNA-Seq, and exom sequencing which are used to identify point mutations and variations against a reference genome. The last 10 years have transformed our understanding of the cancer genome through a remarkable revolution in genome sequencing technology (2,3). Which means, in theory, there are unlimited ways for something to go wrong and allow cancer to develop. WHOLE-GENOME CHARACTERIZATION OF CANCERS IN THE CLINIC. By 2008, the cost had dropped to $2M (5). Cost-effective approaches to sequencing of the whole exome (i.e., the coding regions of the genome) became available in 2009 (), and the method has been applied to predisposition studies in several cancer types (16–18).The first study in which the whole genome of tumor and normal cells was sequenced examined a patient with acute myeloid leukemia (AML) (). Based on this advanced platform, we can provide the most comprehensive cancer WGS sequencing bioinformatics analysis for our global customers. Currently, cancer patients receive a combination of treatments, such as surgery, radiotherapy and chemotherapy, depending on the type and stage of their cancer. The cost to generate a whole-exome sequence was generally below $1,000. Latest sequencing instruments like NovaSeq and HiSeq have a high output making whole genome sequencing cost effective. In 2001, the Human Genome Project delivered the first draft of the human genome at a cost of $3B (4). Several challenges remain in cancer genome sequencing such as accurately detecting different types of somatic mutations, the difficulty in identifying driver mutations, bioinformatics and analytical challenges in analysing the sequencing data and the cost of whole genome resequencing restricting the … Based on the data collected from NHGRI-funded genome-sequencing groups, the cost to generate a high-quality 'draft' whole human genome sequence in mid-2015 was just above $4,000; by late in 2015, that figure had fallen below $1,500. One clear trend in cancer genome sequencing is that the continuing advance of next-generation technology in terms of data capacity per instrument run and read length will accelerate the rate of sequencing whole genomes, at ever-decreasing costs. In 2012, a human genome can be sequenced for less than $5000. WGS also provides a comprehensive view of changes to a specific tumor DNA sample compared to normal DNA. Whole genome sequencing of tumour cells could help predict the prognosis of a patient's cancer and offer clues to identify the most effective treatment, suggests an international study. “In cancer genomics there are a few dozen genes known to increase cancer risk, but with a standard sequencing run, you would have to sequence the whole genome just to read off those few genes,” Schatz said, adding that adaptive sequencing allows researchers to “pick and choose which molecules we want to read and which can be skipped.” Whole exome sequencing identifies mutations in the DNA sequence of protein-coding genes in a genome and can improve cancer treatment and prognosis. CANCER GENOME SEQUENCING: THE FUTURE. Mutation-based approaches, in contrast, require very deep sequencing. The first attempts at cancer genome sequencing were made in 1997 by the Cancer Genome Anatomy Project, which continued its involvement with the project for years. The mission of the Center for Cancer Research Sequencing Facility (CCR-SF) is to utilize high-throughput sequencing technologies to enrich cancer research and ensure that the NCI community can leverage the leading-edge of Next-Generation Sequencing technology.